Puma Biotechnology Inc. (Nasdaq: PBYI) submitted follow-up data to the Food and Drug Administration for its marketing application for the breast cancer treatment neratinib. The stock price soared $7.00 to close at $41.52.
Puma Biotechnology submits follow-up data
July 22, 2016 at 20:14 PM EDT
